By Brazil Stock Guide – Brazilian pharmaceutical company EMS is set to announce the acquisition of Medley, the generics drug business owned by France’s Sanofi, in a deal valued at about R$3.2 billion ($600 million).
The transaction would combine two of the most recognizable brands in Brazil’s generics industry. Together, EMS and Medley account for roughly one quarter of the country’s generics drug market, a level of concentration that is likely to draw scrutiny from Brazil’s antitrust regulator, the Administrative Council for Economic Defense (Cade).
Given EMS’s leadership position in the sector and Medley’s continued relevance among the largest generics producers — despite having lost market share after once leading the segment — the deal is expected to undergo a detailed regulatory review. The antitrust regulator could impose conditions or restrictions before granting approval.
A generics consolidation
EMS belongs to Grupo NC, controlled by entrepreneur Carlos Sanches. The company expanded rapidly after Brazil introduced regulations in the early 2000s that opened the pharmaceutical market to generic medicines, allowing domestic manufacturers to produce lower-cost versions of branded drugs.
Over the past two decades, EMS has built one of the country’s largest pharmaceutical operations, supported by a broad generics portfolio and an extensive distribution network across pharmacies.
Adding Medley would further reinforce that scale, consolidating EMS’s position in a segment where pricing power, distribution reach and manufacturing capacity are critical competitive advantages.
Sanofi unwinds a Brazilian bet
Medley became part of Sanofi in 2009, when the French pharmaceutical group acquired the Brazilian generics company for roughly R$1.5 billion. At the time, multinational drugmakers were seeking stronger exposure to emerging markets and the fast-growing generics business.
In recent years, however, global pharmaceutical groups have increasingly shifted their focus toward innovative and specialty medicines, reducing their exposure to high-volume generics operations.
The potential sale of Medley reflects that broader strategic repositioning.
Campinas pharma hub
Both companies maintain major industrial operations in the Campinas region in the state of São Paulo, one of Brazil’s most important pharmaceutical manufacturing clusters.
According to people familiar with the matter, the two brands are expected to continue operating independently, at least initially, preserving Medley’s identity in pharmacies while allowing EMS to integrate operations gradually.
Still, the final contours of the deal could depend on Cade’s review. Antitrust authorities may analyze concentration not only at the company level but also across specific medicines or therapeutic categories before clearing the transaction.